NATCO Pharma Limited has reported the receipt of a demand notice from the National Pharmaceutical Pricing Authority. The communication, dated May 12, 2026, involves an alleged overcharging claim related to two of the company’s products. The total demand amount is ₹4,92,25,923, covering the period between April 2023 and November 2023. The company has clarified that this event does not have any material impact on its financial or operational activities.
Details of the Pricing Notice
The demand notice issued to NATCO Pharma Limited pertains to an investigation into drug pricing compliance. The regulatory authority has directed the company to deposit a total of ₹4,92,25,923. This figure represents an aggregate of the alleged overcharged amount, associated penalties, and accrued interest.
Scope and Period of Allegation
According to the notice, the allegations are specific to two drugs marketed by the company. The period under review for these pricing concerns spans from April 2023 to November 2023. The company is currently reviewing the notice to assess its further course of action.
Impact Assessment
NATCO Pharma Limited has stated that the receipt of this notice has no material impact on its financial performance, ongoing business operations, or other corporate activities. The company maintains that its current business operations remain stable despite the specific regulatory demand.
Source: BSE
